Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Liver cancer, Secondary cancers
Closed
Phase 2
This trial is looking at having a new drug called volrustomig (MEDI5752) on its own for liver cancer. It is also looking at volrustomig in combination with bevacizumab or lenvatinib.
It is open to people with a type of liver cancer called hepatocellular carcinoma (HCC).
You might be able to join the trial if you have liver cancer that has spread into surrounding tissues or to another part of the body. Or you can’t have surgery to remove it.
Recruitment start: 18 September 2023
Recruitment end: 30 June 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Richard Hubner
AstraZeneca
Last reviewed: 29 June 2025
CRUK internal database number: 19441
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
